Camel nanobodies broadly neutralize SARS-CoV-2 variants
Jessica Hong(National Cancer Institute), Mitchell Ho(National Institutes of Health), Hyung Joon Kwon(National Cancer Center), Hua Ren(Ruijin Hospital), Jianghai Zhu(Leidos (United States)), Venkata P. Dandey(Triangle), Mario J. Borgnia(National Institutes of Health), Kevin John Butay(Triangle), Negin P. Martin(National Institute of Environmental Health Sciences), Raúl E. Cachau, Dominic Esposito(Leidos (United States)), Hang Xie(Nanjing University of Chinese Medicine), Dan Li(Zhejiang Provincial People's Hospital), Miao Xu(National Center for Advancing Translational Sciences), T. Jake Liang(National Institutes of Health), Catherine Z. Chen(National Institutes of Health), Zhijian Duan(University of California, Davis), Uriel Ortega‐Rodriguez(Center for Biologics Evaluation and Research)
Cited by 13
Related Papers
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
|ACS Pharmacology & Translational Science|2020|225
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery
|SLAS DISCOVERY|2020|192